BlackRock Group’s Pacific Biosciences PACB Stock Holding History

BlackRock Group’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.32M	Sell	346,511 -6,444	-2%	-$46.8K	﹤0.01%	2000
2016 Q3	$3.16M	Buy	352,955 +17,891	+5%	+$150K	﹤0.01%	1336
2016 Q2	$2.36M	Buy	335,064 +13,766	+4%	+$126K	﹤0.01%	1457
2016 Q1	$2.73M	Buy	321,298 +17,397	+6%	+$171K	﹤0.01%	1356
2015 Q4	$3.99M	Sell	303,901 -32,880	-10%	-$295K	﹤0.01%	1175
2015 Q3	$1.23M	Sell	336,781 -121,728	-27%	-$595K	﹤0.01%	1762
2015 Q2	$2.64M	Sell	458,509 -92,511	-17%	-$535K	﹤0.01%	1410
2015 Q1	$3.22M	Sell	551,020 -94,691	-15%	-$653K	﹤0.01%	1283
2014 Q4	$5.06M	Buy	+645,711	New	+$4.13M	﹤0.01%	1123
2013 Q4	–	Sell	-13,520	Closed	-$75K	–	2752
2013 Q3	$75K	Buy	+13,520	New	+$46.9K	﹤0.01%	2651

Other funds holding PACB

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

BlackRock Group's PACB Position: Q4 2016 in Review

BlackRock Group reduced its Pacific Biosciences (PACB) stake by 1.8% in Q4 2016, selling an estimated $46.8K and leaving 346,511 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2000.

BlackRock Group first reported a position in PACB in Q3 2013 and has held it in 10 quarters since. The position peaked at $5.06M in Q4 2014. 115 funds tracked by Wall St. Rank hold PACB as of Q4 2016.

BlackRock Group held 346,511 shares of Pacific Biosciences worth $1.32M as of Q4 2016.
BlackRock Group sold 6,444 Pacific Biosciences shares in Q4 2016, an estimated $46.8K.
Pacific Biosciences made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2000 holding.
BlackRock Group first reported a position in Pacific Biosciences in Q3 2013 and has held it in 10 quarters since.
BlackRock Group's Pacific Biosciences position peaked at $5.06M in Q4 2014.
115 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.